Litigation Details for Janssen Pharmaceuticals, Inc. v. Mylan Laboratories Ltd. (Fed. Cir. 2023)

« Back to Dashboard

Janssen Pharmaceuticals, Inc. v. Mylan Laboratories Ltd. (Fed. Cir. 2023)

Docket		Date Filed	2023-06-20
Court	Court of Appeals for the Federal Circuit	Date Terminated	2025-03-28
Cause		Assigned To
Jury Demand		Referred To
Patents	10,143,693; 9,439,906
Link to Docket	External link to docket

Details for Janssen Pharmaceuticals, Inc. v. Mylan Laboratories Ltd. (Fed. Cir. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-06-20				External link to document
2023-06-20	22		launch. [1] From U.S. Patent No. 10,143,693; https://patents.google.com/patent/US10143693B2/en?oq=10%…-7 and 9-14 of United States Patent No. 10,143,693 (“the ’693 patent”) and Mylan’s products that are…Hatch-Waxman case involving Janssen’s U.S. Patent No. 10,143,693 (the “693 Patent”), listed in the Orange Book for…Claims 1-3, 5-7, and 9-29 of U.S. Patent No. 10,143,693 (the “693 Patent”). 15. It … “Plaintiffs”) concerning U.S. Patent No. 10,143,693 (“the ’693 patent”). In their Disclosures of Asserted	External link to document

Janssen Pharmaceuticals v. Mylan Laboratories Ltd. 23-2042: Litigation Summary, Patent Analysis, and Generic Entry Risk

Last updated: August 16, 2026

Janssen Pharmaceuticals, Inc. v. Mylan Laboratories Ltd., No. 23-2042, concerns Janssen’s patent protection for Invega Sustenna, a long-acting injectable formulation of paliperidone palmitate used to treat schizophrenia and related psychiatric disorders. The Federal Circuit affirmed the district court’s determination that Janssen’s asserted dosing-regimen claims were invalid as obvious. The ruling materially weakened Janssen’s U.S. patent position and reduced the legal barrier to Mylan’s abbreviated new drug application, or ANDA, product.

The case is part of broader litigation involving U.S. Patent No. 9,439,906, which covers a loading-dose and maintenance-dose regimen for once-monthly paliperidone palmitate injections. The Federal Circuit reached a similar conclusion in related litigation involving Teva Pharmaceuticals, finding the asserted claims obvious under 35 U.S.C. § 103.[1]

What drug and patent were at issue in Janssen v. Mylan?

The dispute involved Invega Sustenna, whose active pharmaceutical ingredient is paliperidone palmitate. Janssen markets the product as a long-acting injectable antipsychotic.

Item	Information
Brand	Invega Sustenna
Active ingredient	Paliperidone palmitate
Dosage form	Extended-release injectable suspension
Administration	Intramuscular injection
Primary use	Schizophrenia and schizoaffective disorder
NDA holder	Janssen Pharmaceuticals, Inc.
FDA NDA	NDA 022264
Asserted patent	U.S. Patent No. 9,439,906
Patent title	Dosing regimen for long-acting injectable paliperidone
Defendant	Mylan Laboratories Ltd.
Federal Circuit docket	No. 23-2042
Statutory framework	Hatch-Waxman Act and 35 U.S.C. § 271(e)(2)

The asserted patent describes a regimen using an initial 234 mg injection, followed by a 156 mg injection approximately one week later, with subsequent monthly maintenance doses. The regimen is designed to reach therapeutic paliperidone concentrations without oral supplementation.

What claims did Janssen assert against Mylan?

Janssen asserted claims directed to administering paliperidone palmitate according to a specific loading and maintenance schedule. The claims generally required:

1. A first deltoid injection of 234 mg-equivalent paliperidone;
2. A second deltoid injection of 156 mg-equivalent paliperidone approximately one week later; and
3. Monthly maintenance injections in the deltoid or gluteal muscle.

The litigation did not center on the chemical identity of paliperidone palmitate alone. It focused on whether the claimed dosing schedule represented a patentable technical advance over existing information concerning paliperidone, long-acting injectables, pharmacokinetics, and clinical dosing.

That distinction matters commercially. Janssen’s broader product and formulation protection was not equivalent to the asserted dosing-regimen claims. The ruling primarily affected the patent claim set that Janssen relied on to delay generic approval and launch.

What was the district court’s ruling?

The district court held the asserted claims invalid for obviousness. Mylan challenged the patent through the ANDA process, and Janssen brought an infringement action under the Hatch-Waxman framework.

The district court found that a skilled artisan would have had reason to pursue the claimed regimen based on the prior art and would have had a reasonable expectation of success. The court treated the claimed dose sequence as an optimization of known variables rather than an invention requiring an inventive step.

The court’s analysis addressed:

• The known use of paliperidone and paliperidone palmitate;
• Prior disclosures concerning long-acting injectable antipsychotics;
• The desirability of avoiding oral supplementation;
• The relationship between loading doses and therapeutic plasma concentrations;
• The ability to adjust dose size, timing, and injection site through routine pharmacokinetic work; and
• Evidence that the claimed schedule was not outside the predictable range of available options.

The district court’s judgment gave Mylan a favorable basis for seeking FDA approval of its generic product, subject to regulatory review and any remaining enforceable patent or exclusivity rights.

How did the Federal Circuit decide case No. 23-2042?

The Federal Circuit affirmed the district court’s obviousness determination. The appellate court reviewed the legal conclusion of obviousness de novo and the underlying factual findings for clear error.

The Federal Circuit’s reasoning followed the framework applied in related Invega Sustenna litigation. It concluded that the prior art provided a sufficient reason to select the claimed dose regimen and that the evidence supported a reasonable expectation of success.

The ruling rejected Janssen’s effort to characterize the claimed regimen as a nonobvious clinical breakthrough. The court treated the evidence as showing that the relevant dosing parameters could be selected through ordinary pharmaceutical development, including pharmacokinetic modeling and dose-ranging work.

The court also considered Janssen’s objective indicia of nonobviousness, including commercial success, industry recognition, and alleged unexpected results. Those considerations did not overcome the strength of the prior-art case. The Federal Circuit emphasized that objective evidence must have a sufficient nexus to the claimed invention. Commercial success attributable to the overall Invega Sustenna product does not automatically establish nonobviousness of a particular dosing regimen.

Why did Janssen lose on obviousness?

Was there a motivation to combine the prior art?

Yes. The Federal Circuit accepted the conclusion that a skilled artisan would have been motivated to combine disclosures concerning paliperidone, long-acting injectable formulations, and dosing regimens.

The relevant motivation included the clinical need for:

• Rapid achievement of therapeutic concentrations;
• Avoidance of oral supplementation;
• A predictable transition to monthly maintenance dosing; and
• A regimen compatible with established long-acting antipsychotic practices.

The court did not require a prior-art reference to disclose the exact claimed regimen in a single document. Obviousness can arise from combining references where the combination is supported by a reasoned technical rationale.

Did Janssen show unexpected results?

Janssen argued that the claimed regimen produced unexpected pharmacokinetic and clinical benefits. The Federal Circuit did not find that evidence sufficient to defeat obviousness.

The key issue was comparative proof. Unexpected results must generally be shown across the full scope of the claims and compared against the closest prior art. Evidence showing that the regimen worked, without demonstrating an unexpected difference over the prior-art alternatives, has limited weight.

Did commercial success protect the patent?

No. Invega Sustenna had substantial commercial value, but commercial success alone did not establish patent validity. The relevant question was whether sales resulted from the patented dosing features rather than from other factors, including:

• The underlying active ingredient;
• Janssen’s regulatory approval;
• Physician familiarity with the product;
• The product’s extended-release injectable format;
• Janssen’s sales and distribution network; and
• Other unasserted intellectual-property rights.

The Federal Circuit found the nexus evidence insufficient to outweigh the prior-art showing.

What was the relationship to Janssen v. Teva?

Janssen v. Teva involved the same core patent and the same Invega Sustenna dosing regimen. In 2024, the Federal Circuit affirmed the invalidity of the asserted claims in that litigation.[1]

The Teva decision was significant for the Mylan appeal because it addressed the principal technical and legal issues surrounding the patent. The Federal Circuit’s treatment of the prior art, reasonable expectation of success, and objective indicia created a highly unfavorable framework for Janssen’s parallel enforcement efforts.

Issue	Janssen v. Teva	Janssen v. Mylan
Product	Invega Sustenna	Invega Sustenna
Active ingredient	Paliperidone palmitate	Paliperidone palmitate
Core patent	U.S. Patent No. 9,439,906	U.S. Patent No. 9,439,906
Central issue	Obviousness	Obviousness
Federal Circuit result	Claims held obvious	District court judgment affirmed
Commercial impact	Weakened patent barrier	Reduced Mylan launch risk

The related decisions limit Janssen’s ability to rely on the ’906 patent against multiple ANDA applicants. Once the patent’s asserted claims were held invalid, parallel defendants gained a substantially stronger path toward approval and market entry.

What is the Orange Book status of Invega Sustenna?

FDA’s Orange Book identifies patent and exclusivity information submitted by the NDA holder. Invega Sustenna’s listed patent protection has included patents directed to the product’s formulation, active ingredient, and dosing regimen.[2]

The ’906 patent was the principal patent associated with the once-monthly loading-dose regimen litigated against generic applicants. Its invalidation removes the principal asserted dosing-regimen barrier in these cases, although Orange Book status must be assessed by patent number and claim scope rather than by the brand name alone.

FDA approval of a generic product also depends on the ANDA certification, regulatory completeness, labeling, manufacturing readiness, and any remaining enforceable patents. A patent invalidity ruling does not itself compel FDA approval on a fixed date.

What exclusivity did Invega Sustenna receive?

Invega Sustenna was approved in 2009. Its original regulatory exclusivity periods have expired. The product’s remaining market protection therefore depends primarily on patents, pediatric exclusivity where applicable, and the timing of ANDA approvals.

The case did not create new FDA exclusivity. It addressed patent enforceability and validity under the Hatch-Waxman litigation process.

When does Invega Sustenna lose patent exclusivity?

The relevant patent term for the ’906 patent extended into the mid-2020s, subject to statutory patent-term adjustment and any applicable pediatric extension. The Federal Circuit’s invalidity ruling is commercially more important than the nominal expiration date because an invalid patent cannot be enforced through its remaining term.

Other Janssen patents may have different expiration dates and claim scopes. A complete launch analysis must separate:

• Formulation patents;
• Active-ingredient or salt patents;
• Dosing-regimen patents;
• Method-of-use patents;
• Device or manufacturing patents; and
• Any patents listed for particular strengths, administration routes, or indications.

The ’906 decision does not automatically invalidate every patent associated with paliperidone palmitate.

What generic entry risks exist after the Federal Circuit ruling?

Mylan’s litigation position improved materially. The ruling eliminates the principal adverse merits judgment associated with the ’906 patent and lowers the risk that the patent would block approval or trigger a long post-approval injunction.

Potential generic launch scenarios include:

Scenario	Commercial effect
FDA approval after resolution of remaining patents	Mylan may launch, subject to regulatory conditions
Approval with remaining patent certification disputes	Launch timing may depend on additional litigation
Settlement with Janssen	Entry date may be delayed or structured under agreed terms
At-risk launch	Mylan could launch before final resolution of other patent issues, assuming legal and commercial risk
Limited-label launch	Mylan may omit patented indications or dosing instructions if permitted

The legal risk is lower for the specific loading-dose regimen covered by the ’906 patent. The remaining risk lies in other Orange Book patents, non-patent regulatory barriers, manufacturing validation, supply capacity, and any settlement restrictions.

Are biosimilar risks relevant to Invega Sustenna?

No. Invega Sustenna is a chemically defined small-molecule drug product, not a biologic subject to the biosimilar pathway under the Public Health Service Act.

Generic competition would proceed through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The relevant competitors are generic manufacturers, including Mylan, rather than biosimilar sponsors.

This distinction affects:

• FDA approval standards;
• Patent certification procedures;
• Interchangeability rules;
• Substitution at the pharmacy level; and
• Regulatory exclusivity analysis.

What patent-strength conclusions follow from the case?

The ’906 patent had limited durability against an obviousness challenge because its claims were concentrated on a dosing schedule built from variables that the court considered predictable.

Strengths of Janssen’s position

• The product had substantial commercial use.
• The regimen provided a clinically useful loading and maintenance schedule.
• Janssen had regulatory and market evidence supporting product value.
• The claims were directed to a specific administration sequence rather than an entirely open-ended treatment method.

Weaknesses of Janssen’s position

• The claimed parameters were susceptible to characterization as routine optimization.
• The prior art supplied motivation to develop a monthly injectable regimen.
• The expectation of success was supported by pharmacokinetic and clinical evidence.
• Commercial success was not sufficiently tied to the claimed dosing limitations.
• Related litigation exposed the same patent to repeated invalidity challenges.

The case illustrates the vulnerability of pharmaceutical dosing patents when the claimed variables can be selected from known clinical and pharmacokinetic ranges.

Did the parties enter a settlement agreement?

The Federal Circuit decision resolved the appellate judgment. The publicly reported merits outcome is an affirmance of the invalidity determination. The ruling does not establish a separate commercial launch agreement that would supersede the patent judgment.

Any confidential business terms, supply arrangements, launch licenses, or non-patent dispute resolutions would not be inferred from the appellate decision. The legally operative result is that Janssen cannot rely on the asserted ’906 claims as a valid patent barrier against Mylan.

What revenue exposure does Janssen face?

Invega Sustenna is a major Janssen product, and generic entry could create significant price and volume pressure. The commercial impact depends on:

• The number of approved generic applicants;
• The timing of the first commercial launch;
• The availability of alternative paliperidone products;
• Payer substitution policies;
• Generic discounts;
• Physician and patient persistence with long-acting therapy; and
• Janssen’s ability to shift demand to other products or formulations.

Generic erosion is usually gradual for injectable products when manufacturing complexity, clinician familiarity, and distribution requirements slow substitution. The risk is still material because a successful long-acting injectable generic can compete directly on the same therapeutic and dosing attributes.

Key Takeaways

• Janssen v. Mylan, No. 23-2042, involved Invega Sustenna and U.S. Patent No. 9,439,906.
• The patent covered a loading-dose and monthly maintenance regimen for paliperidone palmitate.
• The Federal Circuit affirmed the determination that the asserted claims were obvious.
• The ruling materially reduced Janssen’s ability to block Mylan through the ’906 patent.
• Invega Sustenna is regulated as a small-molecule drug, so generic entry proceeds through an ANDA, not a biosimilar application.
• The decision does not automatically invalidate every Janssen patent covering paliperidone palmitate.
• Remaining launch risk depends on other Orange Book patents, FDA status, manufacturing readiness, and any commercial settlement.
• The case strengthens the position of generic applicants challenging dosing-regimen patents based on predictable pharmacokinetic optimization.

FAQs

What is Janssen Pharmaceuticals v. Mylan Laboratories Ltd. docket 23-2042 about?

It is a Federal Circuit patent appeal involving Janssen’s Invega Sustenna dosing-regimen patent, U.S. Patent No. 9,439,906, and Mylan’s proposed generic paliperidone palmitate product.

Did the Federal Circuit invalidate the entire Invega Sustenna patent estate?

No. The decision addressed the asserted claims and did not automatically invalidate every patent covering Invega Sustenna, paliperidone palmitate, its formulation, manufacturing process, or approved uses.

Can Mylan launch generic paliperidone palmitate immediately after the decision?

Not necessarily. Launch depends on FDA approval, the status of other patents, ANDA certifications, manufacturing readiness, and any settlement or regulatory conditions.

Is Invega Sustenna protected by a biologic exclusivity period?

No. Invega Sustenna is a small-molecule drug product. Its generic competition is governed by the ANDA pathway.

Why are dosing-regimen patents vulnerable to obviousness challenges?

Courts may find such claims obvious when the prior art identifies the drug, delivery system, clinical objective, and relevant pharmacokinetic variables, and when selecting the claimed dose and timing would have been a predictable development exercise.

References

1. U.S. Court of Appeals for the Federal Circuit. (2024). Janssen Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc., 97 F.4th 915.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,439,906: Dosing regimen for long-acting injectable paliperidone.
4. U.S. Court of Appeals for the Federal Circuit. (2024). Janssen Pharmaceuticals, Inc. v. Mylan Laboratories Ltd., No. 23-2042.